Pre-existing and acquired point mutations in BCR-ABL1 kinase are detected in B23% of imatinib-naive and 50-90% of imatinibresistant CML-CP patients, respectively. 3 Moreover, BCR-ABL1 kinase mutants resistant to second-and third-generation TKIs emerged, for example due to new and/or compound mutations. 5, 6 Thus, CML cells are elusive targets even for the most advanced TKI therapies due to continuous accumulation of point mutations in BCR-ABL1 kinase, which encode the resistance to next generations of TKIs. 7 Point mutations usually result from misrepair/lack of repair of enhanced oxidative DNA damage arising from reactive oxygen species (ROS). 8 The potential role of ROS-induced oxidative DNA damage in accumulation of point mutations in CML-CP cells was highlighted by our previous studies, showing that not only imatinib-naive but also imatinib-treated LSCs and/or LPCs from CML-CP patients and CML-CP-like BCR-ABL1 transgenic mice contained 2-6 times more ROS and oxidized bases in comparison with their normal counterparts. 9, 10 In addition, anti-oxidants such as vitamin E reduced ROS and accumulation of TKI-resistant BRC-ABL1 kinase mutations in vitro.
11
To determine whether anti-oxidants may have clinical application, NSG mice were injected with CD34 þ cells obtained from five CML-CP patients with no detectable colonies carrying TKI-resistant mutations. These mice were either untreated or /SzJ (NSG) mice (Jackson Laboratory) were untreated (white bars) or treated with B400 international units of vitamin E ((±)-a-Tocopherol (Sigma)) per kilogram of body mass (gray bars) for 1 week. ROS was measured by dichlorofluorescin diacetate (DCFDA) fluorescence in bone marrow cells (BMC) and splenocytes (SPL) as described before; 9 *P ¼ 0.023, **Po0.001. (b) NSG mice were treated with 25 mg/kg busulfan (Sigma) 30 h before intravenous injection of 0.5 Â 10 6 CD34 þ cells from freshly diagnosed CML-CP patients. Vitamin E was administered daily by oral gavage for 12 weeks. Human cells were detected in total BMC SPL populations by flow cytometry using AmCyan-1-conjugated antihuman CD45 antibody (BD Pharmingen). Figure 1b were incubated with 1 mM imatinib, or left untreated, for 7 days in the absence of growth factors, and then plated in methylcellulose (MethoCult, Stem Cell Technologies) in the presence of 100 ng/ml stem cell factor, 100 ng/ml Flt-3 ligand, 20 ng/ml interleukin 3, 20 ng/ml granulocyte-colony-stimulating factor and 20 ng/ml interleukin 6. Total colonies/mouse and imatinib-resistant colonies were detected and calculated after 7 days. BCR-ABL1 kinase from imatinibresistant colonies was amplified by reverse transcription-PCR and sequenced as described before.
11 Vitamin E treatment inhibited the appearance of imatinib-resistant colonies; P ¼ 0.002, Student's t-test. treated with vitamin E, which reduced ROS by approximately twofold (Figure 1a) . 9, 11 Human CD45 þ cells collected from bone marrows and spleens of NSG mice formed colonies in vitro, and vitamin E treatment did not affect the engraftment (Figure 1b) . Imatinib-resistant clones carrying either E255K or T315I BCR-ABL1 kinase mutations were detected in three out of five untreated xenografts, but in none of the vitamin E-treated samples (Table 1 ).
In conclusion, we postulate that anti-oxidants such as vitamin E may be applicable in prevention of TKI-resistance, in particular of that driven by BCR-ABL1 kinase mutations. Moreover, as imatinibtreated CML-CP LSCs and LPCs continue to accumulate high levels of ROS resulting in TKI-resistant mutations, 9, 10 anti-oxidant treatment could be combined with TKIs to extend/improve the therapeutic effects of ABL1 kinase inhibitors. This speculation is reinforced by the observation that anti-oxidants vitamin E and N-acetyl-cysteine reduced the percentage of the resistant clones emerging in vitro from imatinib-treated BCR-ABL1-positive cells. 
